Greenlight Capital’s Capri Holdings Position Now ‘Medium-Sized’

Gainers Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) shares surged 265.5% to close at $15.35 on Tuesday after the company received a written pre-investigational new drug (pre-IND) response from the FDA regarding MMS019.